ClinicalTrials.gg
RecruitingNCT05768477EC_PC_AZSTLUpdated Nov 3, 2026

Different Treatments in Chronic Pain Patients.

An observational study in Chronic Pain and Nociplastic Pain, sponsored by University Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University Ghent · Observational

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 79 studies in Chronic Pain with a site in Belgium — 18 open to participants now, 21 under way, none of them phase 3. Chronic Pain · Belgium.

Planned enrollment
8th of 32
1,000 · median 167
Started
2023
with 5 others
Observational
32 of 79
11 open now
Primary completion
2027-09
later than 12 of 20 live
Registered
63rd of 79
by date
Lead sponsor
4 of 79
University Ghent

Among the 79 studies in Chronic Pain with a site in Belgium, this one is the 8th largest by planned enrollment of the 32 observational ones that give a count, is one of 6 that started in 2023, is one of 32 observational ones, reaches primary completion later than 12 of the 20 other live ones, and was the 63rd registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

18 of the 79 studies in Chronic Pain with a site in Belgium are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Chronic Pain with a site in Belgium, or all of them as a file.
02

Study summary

The goal of this observational study is to compare different treatment options in a chronic pain population. The main questions it aims to answer are:

  • What is the effectiveness of the different therapy options in the pain center of Sint-Lucas on outcomes related to pain and disability?
  • What are predictive factors for the different therapy options in the pain center of Sint-Lucas? Which factors predict improvement in pain related outcomes?

Participant data will be gathered as part of their routine care. They can be advised to 4 different treatment options:

  • Consultations with the pain specialist
  • Interventions by the pain specialist (infiltrations, denervations)
  • Baxter therapy
  • Interdisciplinary treatment

Researchers will compare patients with different dominant pain mechanisms to see which treatment are most effective for which dominant pain mechanisms.

Read the detailed description

The aim of the present study is to describe the natural flow of the chronic pain patients at the pain center AZ Sint-Lucas. Patients will be examined before starting the therapy, and receive standardized questionnaires at several fixed time points (before, during, and after their therapy trajectory). Information about the present dominant pain mechanism will be gathered during the examination. The questionnaires will gather demographic data, information about the present dominant pain mechanism, psychosocial factors, catastrophizing, fear and avoidance, illness perceptions, fatigue and information about therapy success. During the examination, typical signs of a dominant nociplastic pain mechanism will be gathered. By processing the data of the questionnaires and the examination, knowledge about (1) the amount of patients with a dominant nociplastic pain mechanism at intake, (2) the treatment trajectory for a specific diagnosis, and (3) the prediction of the therapy effect and prognosis will be obtained.

03

Conditions studied

  • Chronic Pain
  • Nociplastic Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population will be patients attending the pain center of AZ Sint-Lucas in Ghent, a secondary care center for chronic pain patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults
  • Chronic pain patients
  • Dutch speaking, or good understanding

Exclusion criteria

Exclusion Criteria:

  • Adults unable to give consent
  • Adults who do not understand Dutch
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
18 Months
Patient registry
Yes

Groups and cohorts

  • Chronic pain patients

    Chronic pain patients with a dominant nociceptive pain mechanism, a dominant neuropathic pain mechanism and a dominant nociplastic pain mechanism. They will receive different treatments: Consultations, Interventions (injections, denervations...), Baxter therapy and interdisciplinary treatment.

    Other: Consultation · Procedure: Interventions · Drug: Baxter therapy · Behavioral: Interdisciplinary therapy

Interventions

  • OtherConsultation

    Consultation with the pain specialist, which might entail prescription of medication of vitamins.

  • ProcedureInterventions

    Facet injections, nerve denervations, infiltrations, Qutenza, Spinal Cord Stimulation, Transcutaneous Electrical Nerve Stimulation

  • DrugBaxter therapy

    Ketamine or Linisol baxter therapy

  • BehavioralInterdisciplinary therapy

    Interdisciplinary therapy provided by the physiotherapist, psychologist and occupational therapist.

06

What researchers measure

Primary outcomes

  1. Change in Pain disability from baseline until 18 months

    Pain Disability Index, ranges from zero to 70, with a higher score indicating more pain-related disability

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

  2. Change in Pain intensity from baseline until 18 months

    Numeric Rating Scale for pain intensity in the past week, ranges from zero to 100, with a higher score indicating a higher pain intensity

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

  3. Change in Pain Frequency from baseline until 18 months

    Questions

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

  4. Change in Functionality from baseline until 18 months

    Patient Specific Complaints questionnaire, using a Numeric Rating Scale, ranging from zero to 100, with a higher score indicating a higher amount of functional disability

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

  5. Change in Quality of Life from baseline until 18 months

    EuroQol-5D questionnaire

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

Secondary outcomes

  1. Change in Post exertional malaise from baseline until 18 months

    Questions based on the criteria for Chronic Fatigue Syndrome.

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

  2. Change in Quality of Life from baseline until 18 months

    EuroQol - 5D, five questions about health range from one to three with a higher score indicating more difficulties. One question about perceived health ranges from zero to 100 with a higher score indicating better health.

    Time frame: 0 weeks, 4 weeks, 10 weeks, 6 months, 12 months, 18 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The personal data will be shared with the personal electronic patient file of AZ Sint-Lucas, of each patient. Sharing of data will be done upon reasonable request, and only for research purposes, after publication of the results. Data will be shared via a restricted data repository (FAIRsharing.org)

Time frame: The data will not be transferred to a third country. The ethical committee of the pain center of AZ Sint-Lucas did not allow for data transfer upon reasonable request.

Access criteria: The data will not be transferred to a third country.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Sep 2027, 53 months after the start.

Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 53 months is above that.

Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Apr 2026 → Sep 2027 and completion Jun 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2022
First posted
Mar 14, 2023
StartActual
Apr 6, 2023
Primary completionEst.
Sep 2027was Apr 2026
CompletionEst.
Dec 31, 2027was Jun 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2026→Sep 2027
Nov 3, 2026
Study completion
Jun 30, 2027→Dec 31, 2027
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Primary completion Apr 2026→Sep 2027
    Study completion Jun 30, 2027→Dec 31, 2027
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05768477
Lead sponsor
University Ghent
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Apr 6, 2023
Primary completion
Sep 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Jessica Van Oosterwijck, Professor
Contact
jessica.vanoosterwijck@ugent.be
+32 9 332 69 19
Elise Cnockaert
Contact
elise.cnockaert@ugent.be
+32 9 332 56 35
Jessica Van Oosterwijck
principal investigator · Department of Rehabilitation Sciences, Faculty of Health Sciences, Ghent University, Belgium

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion